Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.51 |
| ▸ | HTR2C | P28335 | 7/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 2/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8786271 | 0.89 | HTR1A (0.48) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| SCHEMBL7332557 | 0.83 | HTR1A (0.51) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| SCHEMBL17080919 | 0.83 | HTR1A (0.51) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| SCHEMBL9684901 | 0.83 | PDE3B (0.51) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| Bromide SCHEMBL7797195 | 0.81 | HTR1A (0.50) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| SCHEMBL9685616 | 0.81 | HTR1A (0.60) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| SCHEMBL1325447 | 0.80 | HTR1A (0.49) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| SCHEMBL1324801 | 0.80 | HTR1A (0.49) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| SCHEMBL9685780 | 0.80 | HTR1A (0.50) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| SCHEMBL8114295 | 0.79 | HTR1A (0.48) | HTR1AHTR2CPDE3BPDE3AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | PFIZER INC | 2008-10-30 | — | — | US | disclosed |
| EP-1757292-A1 | Method of treating ocd and tic disorders | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| CN-1780626-A | Treatment of bipolar disorder and related symptoms | PFIZER (US) | 2006-05-31 | — | — | CN | disclosed |
| EP-1633361-A1 | ANXIETY TREATMENTS WITH ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1633360-A1 | TREATMENT OF PSYCHOTIC AND DEPRESSIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1626722-A1 | METHOD FOR ENHANCING COGNITION USING ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1626723-A1 | TREATMENT OF BIPOLAR DISORDERS AND ASSOCIATED SYMPTOMS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| US-20050004137-A1 | Treatment of psychotic and depressive disorders | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| EP-0478446-B1 | Heterocyclic alkylamines, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1997-11-19 | — | — | EP | disclosed |
| US-5296477-A | Antidepressants | ADIR ET COMPAGNIE (FR) | 1994-03-22 | — | — | US | disclosed |
| US-5268381-A | Antidepressant or anxiolytic compound | ADIR ET COMPAGNIE (FR) | 1993-12-07 | — | — | US | disclosed |
| US-5234924-A | Hypotensive agents | ADIR ET COMPAGNIE (FR) | 1993-08-10 | — | — | US | disclosed |
| US-5196434-A | Antidepressants, anxiolytic agents | ADIR ET COMPAGNIE (FR) | 1993-03-23 | — | — | US | disclosed |
| EP-0478446-A1 | Heterocyclic alkylamines, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1992-04-01 | — | — | EP | disclosed |
| EP-0281309-B1 | PIPERAZINYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| US-4883795-A | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1989-11-28 | — | — | US | disclosed |
| US-4831031-A | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity | PFIZER INC. (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0281309-A1 | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004137-A1 | Treatment of psychotic and depressive disorders | SNCA, NLN, INA | HTR1A 76/4885HTR2C 397/4885PDE3B 4168/4885 |
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | MC2R, NR3C1, CRH | HTR1A 79/4885HTR2C 475/4885PDE3B 2982/4885 |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | DBH, RAP1A, GABRR1 | HTR1A 50/4885HTR2C 417/4885PDE3B 810/4885 |
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | GABBR1, GABRR1, GABBR2 | HTR1A 80/4885HTR2C 518/4885PDE3B 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.